newsfilter
← Latest News
Business Wire·

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform Confirmatory Study Required for Potential FDA Accelerated Approval of TA-ERT Expected